The approval of Sativex for the management of multiple sclerosis (MS) spasticity opened a new opportunity to many patients. In Italy, the healthcare payer can be fully reimbursed by the involved pharma company with the cost of treatment for patients not responding after a 4 week (28 days) trial period (Payment by Results, PbR), and 50% reimbursed with the cost of 6 weeks (42 days) treatment for other patients discontinuing (Cost Sharing, CS). The aim of our study was to describe the Sativex discontinuation profile from a large population of spasticity treated Italian MS patients.
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) / Messina, Silvia; Solaro, Claudio; Righini, Isabella; Bergamaschi, Roberto; Bonavita, Simona; Bossio, Roberto Bruno; Brescia Morra, Vincenzo; Costantino, Gianfranco; Cavalla, Paola; Centonze, Diego; Comi, Giancarlo; Cottone, Salvatore; Danni, Maura Chiara; Francia, Ada; Gajofatto, Alberto; Gasperini, Claudio; Zaffaroni, Mauro; Petrucci, Loredana; Signoriello, Elisabetta; Maniscalco, Giorgia Teresa; Spinicci, Gabriella; Matta, Manuela; Mirabella, Massimiliano; Pedà, Graziella; Castelli, Letizia; Rovaris, Marco; Sessa, Edoardo; Spitaleri, Daniele; Paolicelli, Damiano; Granata, Alfredo; Zappia, Mario; Patti, Francesco. - In: PLOS ONE. - ISSN 1932-6203. - 12:8(2017), p. e0180651. [10.1371/journal.pone.0180651]
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)
Brescia Morra, Vincenzo;
2017
Abstract
The approval of Sativex for the management of multiple sclerosis (MS) spasticity opened a new opportunity to many patients. In Italy, the healthcare payer can be fully reimbursed by the involved pharma company with the cost of treatment for patients not responding after a 4 week (28 days) trial period (Payment by Results, PbR), and 50% reimbursed with the cost of 6 weeks (42 days) treatment for other patients discontinuing (Cost Sharing, CS). The aim of our study was to describe the Sativex discontinuation profile from a large population of spasticity treated Italian MS patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
pone.0180651.pdf
solo utenti autorizzati
Tipologia:
Abstract
Licenza:
Accesso privato/ristretto
Dimensione
1.68 MB
Formato
Adobe PDF
|
1.68 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
